Navigation Links
NxStage Completes Move to Direct Sales In UK
Date:4/8/2013

LAWRENCE, Mass., April 8, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced today that it has completed its move to a direct sales model in the United Kingdom.  NxStage will begin selling the System One™ and related products and services directly in the region through its wholly-owned UK subsidiary, NxStage Medical UK, Ltd.   The Company's former UK distributor, Kimal® Plc., remains a trusted partner, and will continue to assist NxStage with customer service and logistical support.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

"We are excited to expand our direct operations into the UK," said Jeffrey Burbank , Chief Executive Officer of NxStage. "As the next step in our international growth strategy, this move presents us with the opportunity to build upon Kimal's success, strengthen our relationship with customers, and more rapidly take advantage of new product approvals."

"Kimal are so proud of the introduction we have made in the UK with the technology of NxStage.  It is a delight to be able to make such a difference to the lives of patients with renal disease," stated Alan Press , Chief Executive Officer of  Kimal Plc. "Dialysis keeps them alive, NxStage at home gives them their life back!  May many more patients receive this benefit, it really does make a difference.  We wish every success to the NxStage team."

The UK-based NxStage team is solely dedicated to supporting home hemodialysis enabling close alignment and responsiveness with the needs of UK Trusts, health care professionals, and patients. NxStage UK will set up and directly control commercial activities including sales, marketing, and all clinical support activities for the National Health Service (NHS) hospitals managing home hemodialysis programs.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). The System One also has a CE mark and has been cleared by Health Canada. Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road.

About NxStage Medical

NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage Educational Reception at Annual Dialysis Conference Features Celebrity and Former NxStage User Stephen Furst
2. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
3. NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
4. NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
5. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
6. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
7. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
8. Robert Funari Joins NxStage Board of Directors
9. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
10. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
11. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
(Date:6/23/2016)... , June 23, 2016  The National Pharmaceutical ... joined the health policy research organization as its ... , MD, senior vice president and chief scientific ... representative on the NPC Board of Directors. ... that Mallinckrodt has joined us in support of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):